1. Omnichannel has been a buzzword in pharma for nearly a decade — yet most companies still struggle to execute it consistently. What's the
real reason the industry keeps falling short, and what's finally changed in 2026 that makes excellence actually achievable?
2. AI-powered orchestration promises hyper-personalized patient engagement at scale — but pharma operates under some of the strictest compliance and privacy constraints in any industry. Where does the tension between personalization and regulatory risk actually break down in practice, and how are leading companies navigating it?
3. You mentioned four must-have capabilities for a high-impact patient omnichannel strategy. Most companies will claim they already have some version of these — so what separates the organizations that are truly executing from those that are just checking boxes?
4. We talk a lot about reaching patients, but omnichannel success ultimately depends on changing behavior — whether that's adherence, treatment-seeking, or HCP conversations. Where in the patient journey are companies seeing the biggest ROI from omnichannel investment right now, and where is the industry still leaving value on the table?
5. The case studies from top pharmaceutical companies are compelling — but large pharma has resources, technology infrastructure, and data that mid-size and specialty companies simply don't have. What does omnichannel excellence actually look like for an organization that
doesn't have an unlimited budget and a 50-person digital team?
6. If you could eliminate one widely-held belief about omnichannel strategy in pharma — something the industry keeps getting wrong — what would it be, and what should replace it?
